To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

Summary

TQD3606 is a fixed-dose combination of meropenem and avibatam. This study is a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQD3606 injection in a single center, randomized, double-blind, placebo-controlled, single and multiple administration in healthy subjects, and to explore the excretion of TQD3606 in urine. To evaluate the tolerability and safety of injectable TQD3606 after single and multiple dosing in healthy subjects.

Timeline

Start

2022-04

Primary completion

2023-12

Completion

2023-12

Drugs

Indications